Search Results

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Kionex ® (Sodium Polystyrene Sulfonate Suspension USP) for Oral or Rectal use.

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 2024 Jefferies Global Healthcare Conference in New York City.

ANI Pharmaceuticals, Inc. and Alimera Sciences, Inc. announced they have signed a definitive agreement pursuant to which ANI will acquire Alimera for $5.50 per share in cash at closing and one non-tradable contingent value right representing the right to receive up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027.

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Baclofen Oral Suspension, a generic version of the reference listed drug (RLD) Fleqsuvy ® .

ANI Pharmaceuticals, Inc. announced financial results and business highlights for the three months ended March 31, 2024.

ANI Pharmaceuticals, Inc. announced the launch of Levofloxacin Oral Solution, a generic version of the Reference Listed Drug Levaquin®.

ANI Pharmaceuticals, Inc. announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will participate at two upcoming healthcare conferences in New York City as follows.